In vivo characterization of the role of tissue-specific translation elongation factor 1A2 in protein synthesis reveals insights into muscle atrophy by Doig, Jennifer et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In vivo characterization of the role of tissue-specific translation
elongation factor 1A2 in protein synthesis reveals insights into
muscle atrophy
Citation for published version:
Doig, J, Griffiths, LA, Peberdy, D, Dharmasaroja, P, Vera, M, Davies, FJC, Newbery, HJ, Brownstein, D &
Abbott, CM 2013, 'In vivo characterization of the role of tissue-specific translation elongation factor 1A2 in
protein synthesis reveals insights into muscle atrophy' Febs Journal, vol. 280, no. 24, pp. 6528-6540. DOI:
10.1111/febs.12554
Digital Object Identifier (DOI):
10.1111/febs.12554
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Febs Journal
Publisher Rights Statement:
© 2013 The Authors. FEBS Journal published by John Wiley & Sons Ltd on behalf of FEBS
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
In vivo characterization of the role of tissue-specific
translation elongation factor 1A2 in protein synthesis
reveals insights into muscle atrophy
Jennifer Doig1,*, Lowri A. Griffiths1,*, David Peberdy1, Permphan Dharmasaroja1,†, Maria Vera2,
Faith J. C. Davies1, Helen J. Newbery1, David Brownstein3 and Catherine M. Abbott1,3
1 Medical Genetics Section, Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital,
University of Edinburgh, UK
2 Anatomy & Structural Biology, Albert Einstein University, Bronx, NY, USA
3 Research Animal Pathology Core Facility, Queen’s Medical Research Institute, University of Edinburgh, UK
Keywords
motor neuron degeneration; muscle atrophy;
transgenic mice; translation elongation
Correspondence
C. M. Abbott, Medical Genetics Section,
Institute of Genetics and Molecular
Medicine, Molecular Medicine Centre,
Western General Hospital, University of
Edinburgh, Edinburgh EH4 2XU, UK
Fax: +44 131 651 1059
Tel: +44 131 651 1077
E-mail: C.Abbott@ed.ac.uk
†Present address
Department of Anatomy, Faculty of Science,
Mahidol University, Room B128, Bangkok,
10400, Thailand
*These authors contributed equally to this
work.
(Received 17 July 2013, revised 30 August
2013, accepted 26 September 2013)
doi:10.1111/febs.12554
Translation elongation factor 1A2 (eEF1A2), uniquely among translation
factors, is expressed specifically in neurons and muscle. eEF1A2-null
mutant wasted mice develop an aggressive, early-onset form of neurodegen-
eration, but it is unknown whether the wasting results from denervation of
the muscles, or whether the mice have a primary myopathy resulting from
loss of translation activity in muscle. We set out to establish the relative
contributions of loss of eEF1A2 in the different tissues to this postnatal
lethal phenotype. We used tissue-specific transgenesis to show that correc-
tion of eEF1A2 levels in muscle fails to ameliorate the overt phenotypic
abnormalities or time of death of wasted mice. Molecular markers of mus-
cle atrophy such as Fbxo32 were dramatically upregulated at the RNA
level in wasted mice, both in the presence and in the absence of muscle-spe-
cific expression of eEF1A2, but the degree of upregulation at the protein
level was significantly lower in those wasted mice without transgene-derived
expression of eEF1A2 in muscle. This provides the first in vivo confirma-
tion that eEF1A2 plays an important role in translation. In spite of the
inability of the nontransgenic wasted mice to upregulate key atrogenes at
the protein level in response to denervation to the same degree as their
transgenic counterparts, there were no measurable differences between
transgenic and nontransgenic wasted mice in terms of weight loss, grip
strength, or muscle pathology. This suggests that a compromised ability
fully to execute the atrogene pathway in denervated muscle does not affect
the process of muscle atrophy in the short term.
Introduction
Motor neuron disease (MND) is the umbrella term for
a group of neurodegenerative diseases primarily affect-
ing the motor neurons of the spinal cord. The term
covers both the early-onset genetic disorder spinal
muscular atrophy (SMA) and the adult-onset forms of
MND, both sporadic and genetic. The adult form is
often referred to as amyotrophic lateral sclerosis
(ALS). MND has a complex aetiology that has, until
recently, often eluded characterization at a genetic
level, with a few notable exceptions, many involving
Abbreviations
ALS, amyotrophic lateral sclerosis; eEF1A, translation elongation factor 1A; eEF1A1, translation elongation factor 1A1; eEF1A2, translation
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defects in genes encoding molecules involved in RNA
processing [1], together with a recent discovery of a
gene whose product is involved in protein degradation
[2]. Severe muscle atrophy is seen in MND, and the
mechanisms underlying this process have been studied
in many animal and cellular models.
A number of mouse models exist for both SMA and
ALS forms of the disease. In some cases, these involve
targeted mutations in genes that have previously been
implicated in human forms of the disease, but there
are also mouse mutants that model the neurodegenera-
tive process without necessarily involving the same
genetic basis. One such model is the wasted mouse,
which arises from a spontaneous recessive mutation
resulting in deletion of the promoter region and first
noncoding exon of the Eef1a2 gene encoding transla-
tion elongation factor 1A2 (eEF1A2). This 15.8-kb
deletion completely abolishes eEF1A2 protein expres-
sion [3]. Mice homozygous for this deletion develop an
early-onset aggressive form of motor neuron degenera-
tion, characterized by muscle atrophy, tremors and
gait abnormalities soon after weaning. They then dete-
riorate rapidly and die, typically by 28 days [4]. The
onset of this phenotype coincides with a developmental
switch in eEF1A variants in muscle.
There are two independently encoded translation
elongation factor 1A (eEF1A) isoforms in mammals,
translation elongation factor 1A1 (eEF1A1) and
eEF1A2. Whereas eEF1A1 is almost ubiquitously
expressed, its expression in muscle starts at high levels
at birth, but then declines to become almost undetect-
able by ~ 21 days. Meanwhile, eEF1A2 levels in mus-
cle rise from very low levels at birth to high levels by
21 days after birth [5]. The loss of eEF1A1 in muscle
thus corresponds precisely to the onset of the wasted
phenotype. Within brain and spinal cord, there is
exclusive expression of one or other eEF1A isoform,
depending on cell type, with neurons expressing only
eEF1A2 and glial cells expressing only eEF1A1 [6,7].
Wasted mice therefore have neither eEF1A1 nor
eEF1A2 expression in muscle or motor neurons
beyond 21 days of age. As eEF1A is essential for
de novo protein synthesis, it is assumed that both mus-
cle cells and neurons will be severely affected by the
mutation. Indeed, in addition to the loss of muscle
bulk, motor neuron pathology is found in wasted mice
[3,7]. From 17 days, nerves retract from motor end-
plates, and by 19 days reactive gliosis is seen in spinal
cord sections. Neurofilament accumulation in the peri-
karya of motor neurons is then seen, and vacuolation
and death of motor neurons is observable by 24 days.
Previous transgenic studies in our laboratory have
shown that Eef1a2 is the only gene responsible for the
wasted phenotype [6]. However, it has never been
established whether the loss of muscle bulk, loss of
muscle function and ultimate death of wasted mice
results from the loss of eEF1A2 in muscle, or whether
the muscle phenotype is caused by denervation atro-
phy resulting from loss of eEF1A2 in the motor neu-
rons. This is an important question, as studies on
other MND-related genes have given contrasting
results. Gavrilina et al. [8] showed in a mouse model
of SMA that transgenic expression of the survival
motor neuron protein (SMN) from a neuronal pro-
moter completely ameliorated the symptoms and res-
cued the phenotype of the mice. However, expression
of SMN exclusively in muscle [driven by the human
skeletal actin (HSA) promoter] failed to rescue the
phenotype, suggesting that the muscle atrophy seen in
these mice is entirely neurogenic in origin. This was
further confirmed by the authors’ analysis of a line
expressing SMN from the HSA promoter, in which
leaky low-level expression was seen in neurons. In this
line, the mice survived for 160 days, showing that even
a low level of expression in neurons has more impact
on the phenotype than high-level expression in muscle.
In contrast, a similar study was carried out in a mouse
model of SMA with respiratory distress, which is
caused by mutations in the Ighmbp2 gene. In this case,
the phenotypic abnormalities could only be corrected
by expression of the wild-type gene in both muscle and
neurons [9,10]. These contrasting results suggest that
there are different mechanisms underlying the neuro-
muscular problems caused by mutations in distinct
genes.
eEF1A2 has not been directly implicated in human
neurodegenerative disease, but a specific missense
mutation in eEF1A2 has been found in two individuals
with severe intellectual disability and epilepsy [11,12].
A subunit of the GTP exchange factor for eEF1A,
eEF1B2, has also been associated with severe intellec-
tual disability [13]. A copy number variant in another
subunit of this complex, eEF1D, has been tentatively
associated with ALS [14].
In all cases of muscle atrophy studied, whether as a
result of starvation, disuse, cancer, or denervation, a
coordinated programme of changes in gene expression
is seen. These coordinately regulated genes have been
termed ‘atrogenes’ (for atrophy-related genes) [15].
Among the most widely studied atrogenes are Fbxo32
(also called atrogin-1 or MAFbx) and MuRF1, both
of which are substantially upregulated in response to
muscle damage. They encode muscle-specific E3 ubiqu-
itin ligases that are regarded as key molecules for the
control of the process of atrophy, targeting specific
proteins for proteasomal degradation [16]. Although
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these atrogenes have been extensively assayed, there is
still some controversy about whether they are actually
essential for the process of muscle atrophy. Murton,
for example, states ‘indeed, while unlikely, the assumed
elevation of MAFbx and MuRF1 mRNA levels culmi-
nating in a decline in muscle mass may merely be the
result of guilt by association’ [17]. On the other hand,
there is very good evidence for a functional role for
these factors from knockout mouse studies, where loss
of function of either gene led to a reduction in dener-
vation-induced muscle atrophy [18].
We set out to establish whether the muscle atrophy
seen in the wasted mouse could be corrected or ame-
liorated by expression of eEF1A2 solely in muscle, or
whether the muscle atrophy was primarily neurogenic
in origin. This allowed us to assess the potential of the
wasted mouse mutant as a model for the process of
motor neuron degeneration; we showed that restora-
tion of eEF1A2 in muscle but not in neurons fails to
rescue the wasted phenotype. We also assayed molecu-
lar markers of muscle atrophy in wasted mice with
and without muscle-specific eEF1A2 transgenes. Both
transgenic and nontransgenic wasted mice showed sig-
nificant levels of upregulation of markers of muscle
damage as assayed by quantitative RT-PCR, but
wasted mice without the transgene showed much more
modest increases in these markers than transgenic
wasted mice when they were assayed by western blot-
ting. This finding is consistent with the predicted (but
not hitherto directly demonstrated) role of eEF1A2 as
a crucial translation factor. The availability of mice all
undergoing denervation atrophy, but both with (wst/
wst transgenic) and without (wst/wst nontransgenic)
the ability to convert the increases in markers of
muscle atrophy seen at the RNA level into similar
increases at the protein level, provides a novel system
for investigation of the mechanisms of muscle
atrophy.
Results
Experimental design
In order to establish whether the weight decline, loss of
grip strength and other abnormalities seen in wasted
mice result from the loss of eEF1A2 activity in muscle
and/or neurons, we set out to dissect out different
aspects of the phenotype by using different promoters to
drive tissue-specific expression of eEF1A2 in transgenic
mice. These were crossed with +/wst heterozygous mice,
and then intercrossed to generate transgenic
wst/wst homozygotes, which were characterized in terms
of expression of eEF1A2 and by phenotypic assays.
The tissue-specific promoters that we used were
designed to force expression of eEF1A2 in neurons
only [the rat neuron-specific enolase promoter (NSE)]
and in muscle only (the human skeletal actin promo-
ter, HSA). A 1.8-kb fragment of the promoter region
of the gene encoding NSE has been previously shown
to contain all of the regulatory elements required for
driving neuron-specific expression in transgenic mice
[19], and numerous studies have demonstrated neuron-
specific transgene expression, using this promoter
region [10,20]. The HSA promoter has been extensively
used in transgenic mice [21]; it is expressed in all skele-
tal muscle types from birth onwards, reflecting the
expression pattern of eEF1A2 in muscle. In each case,
the promoter fragment was ligated to all coding exons
(2–8) of human eEF1A2. We have previously shown
that human eEF1A2 can functionally substitute for
mouse eEF1A2 in transgenic mice [6], and the use of a
human construct allowed us to design RT-PCR assays
to distinguish between expression of endogenous and
transgene-derived eEF1A2.
NSE–eEF1A2
Pronuclear injection of the NSE–eEF1A2 construct
into fertilized mouse oocytes gave rise to three trans-
mitting founder mice. Only two of the resulting lines
(called line B and line C) showed clear expression of
the transgene in brain at the RNA level, and were thus
chosen for further analysis.
With the exception of a single amino acid, human
and mouse eEF1A2 are identical at the amino acid
level. This meant that we were unable to examine pro-
tein expression of the transgene until the final stage of
the crosses, when homozygosity for the wasted allele
meant that there was no confounding expression of
endogenous eEF1A2. When tissues from transgene-
positive homozygous wasted mice were subjected to
western blot analysis, we found that both lines B and
C unexpectedly had expression of the transgene in
both brain and muscle; this could be attributable to
position effects, but the promoter that we generated
by PCR incorporated an artificial restriction site to
facilitate cloning, and we cannot exclude the possibility
that this sequence affected the specificity of expression.
Line B was chosen for further analysis. Figure 1 shows
western blots of eEF1A2 in various tissues from three
mice of each genotype, all at 25 days: wild-type mice
with and without the transgene, and wst/wst homozyg-
otes with and without the transgene. It is clear that,
whereas (as expected) there was no eEF1A2 expression
in any of the nontransgenic wasted mice, levels of
eEF1A2 in muscle and heart of transgenic wasted mice
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were comparable to or even higher than those seen in
nontransgenic wild-type mice [average densitometry
reading relative to glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) of 4.4 in wasted transgenic mus-
cle as compared with 1.5 in wild-type controls].
Similarly, expression of eEF1A2 in brain and spinal
cord of all transgenic mice was higher than that seen
in wild-type mice (average densitometry reading rela-
tive to GAPDH of 6.7 in wasted transgenic muscle as
compared with 2.1 in wild-type controls for brain, and
1.4 as compared with 1.3 in spinal cord), so all trans-
genic wst/wst mice had levels of eEF1A2 that were at
least as high as those of their nontransgenic littermates
in brain, spinal cord, muscle, and heart. Increased
expression of the transgene was more marked in brain
and spinal cord than in muscle, consistent with the
known properties of the NSE promoter. The bottom
panel of Fig. 1 shows that there was no expression of
either endogenous or transgene-derived eEF1A2 in
liver, as expected, and Fig. 2 shows eEF1A2 expres-
sion in an extended panel of tissues from a transgenic
wasted mouse, showing that there was no apparent
ectopic expression of the transgene other than in
muscle.
Immunohistochemistry of eEF1A2 in spinal cord
and brain in the transgenic wasted mice (i.e. where
there is no confounding expression of the endogenous
gene) showed expression of eEF1A2 exclusively in neu-
ronal populations, and particularly strong expression
in Purkinje cells in the cerebellum, and in the motor
neurons of the spinal cord (Fig. S1), reflecting the nor-
mal pattern of expression of eEF1A2. In earlier work,
we showed that, in addition to its high-level expression
in neurons and muscle, eEF1A2 is also expressed in
specific cell types, such as a subset of pancreatic islet
cells [6]. We therefore also used immunohistochemistry
to examine expression in pancreas, and found that, as
expected for the NSE promoter, the transgene was not
expressed in pancreatic islet cells (Fig. S1, right panel),
in contrast to endogenous eEF1A2. There was no evi-
dence of effects on the pancreas of these mice when
sections were examined (data not shown).
Analysis of transgenic wasted mice as compared
with their nontransgenic littermates revealed complete
correction of the wasted phenotype. The mice
appeared healthy and bred normally; most mice were
culled along with normal littermates between 2 and
6 months, but a subset were retained with no apparent
ill-effects for 12 months, so we have no evidence that
the lifespan was reduced relative to wild-type mice.
They had spleens and thymuses of normal size, and
showed no tremors or gait abnormalities. Body
weights at 25 days are given in Table 1, and show
that, whereas nontransgenic wst/wst mice were signifi-
cantly smaller than their wild-type littermates, those
that expressed the transgene achieved a similar weight
to wild-type mice, with a significant difference
(P < 0.01) being seen between transgenic and
Fig. 1. Western blots showing expression of eEF1A2 and GAPDH
(as a loading control) in tissues from transgenic and nontransgenic
mice of the transgenic line NSE–EEF1A2-B. Expression from three
mice from each group (wild type, wild type transgenic, wasted,
and wasted transgenic) is shown. *The final two lanes contain
muscle (as an eEF1A2-positive control) and liver (as an eEF1A2-
negative control) samples; in the top four sections, the order is
muscle and then liver on the extreme right, but in the bottom
panel the order is reversed, and liver is loaded first, with muscle
on the extreme right.
Fig. 2. Western blots showing expression of eEF1A2 and GAPDH
(as a loading control) on an expanded panel of tissues from a
wasted mice carrying the transgene from the transgenic line NSE–
EEF1A2-B. M, muscle; H, heart; Br, brain; SC, spinal cord; Li, liver;
K, kidney; Sp, spleen; P, pancreas; C, colon; Lu, lung.
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nontransgenic homozygous wasted mice. The presence
of the transgene in non-wasted mice had no significant
effect on body weight. The NSE–eEF1A2 transgene
thus corrects the loss of muscle bulk seen in wasted
mice, as the majority of body weight loss derives from
a decrease in muscle weight [7]. It is worth noting that
the overexpression seen in muscles and neurons of
wild-type mice carrying the transgene appeared to
cause no ill-effects.
We then went on to test muscle function by analy-
sing grip strength in the mice (Table 2). At 25 days of
age, towards the end-stage of disease, analysis of grip
strength normalized to body weight in both forelimbs
only and all four limbs together showed that wasted
mice carrying the transgene (+/tg, wst/wst; ‘tg’ is used
to designate the presence of the transgene in the gene
symbol) were indistinguishable from wild-type mice
(+/+, +/+), and had significantly higher grip strength
than wasted mice without the transgene (+/+, wst/wst).
This difference was slightly more marked when only
forelimbs were analysed. The poor muscle function
seen in wasted mice is therefore completely corrected
by expression of the transgene.
By all measures applied, therefore, the NSE–
eEF1A2 transgene was sufficient to correct the defects
seen in wasted mice. However, even though expression
of the transgene was enriched in brain as compared
with muscle, it was still expressed at normal levels in
muscle, so this experiment alone was not sufficient to
establish whether the primary cause of disease in
wasted mice is neurological in origin. It is worth not-
ing that the lack of specificity of the NSE promoter
that we observed is unexpected, but not unprecedented
in the literature [22,23]. We therefore sought to express
eEF1A2 specifically in muscle to establish whether this
too would result in correction of the wasted pheno-
type.
HSA–eEF1A2
Pronuclear injection of the HSA–eEF1A2 construct
into fertilized mouse oocytes gave rise to three inde-
pendently derived founder mice that all transmitted
the transgene. None of the three lines corrected any
aspect of the wasted phenotype, in spite of expressing
the transgene at levels comparable to those seen in
wild-type controls. One line was selected for further
analysis.
Western blot analysis of muscle and brain from
transgenic wst/wst mice and controls shows that
eEF1A2 was expressed in muscle of transgene-positive
wasted mice at levels comparable to those seen in con-
trol wild-type mice (Fig. 3; densitometry gave an aver-
age ratio of 1.7 for wasted transgenic mice as
compared with wild-type mice). In contrast, analysis of
brain extracts shows that, whereas endogenous
eEF1A2 was easily detectable in wild-type brain, no
expression was seen in brain of transgenic wasted
mice, suggesting that the HSA promoter operates in a
muscle-specific manner in these lines (note that the
faint band seen in the brains of wasted transgenic mice
in Fig. 3 is actually slightly smaller than eEF1A2, and
the same band can also be seen in nontransgenic
wasted control mice).
In spite of the presence of physiological levels of
eEF1A2 in the muscle of transgenic wst/wst mice, no
amelioration of the phenotype was seen. Growth curve
Table 1. Body weights of mice from NSE–eEF1A2 line B at
25 days. *P < 0.01 for comparison of wasted mice without the
transgene with wild-type mice; those with the transgene are not
significantly different from wild-type mice. SEM, standard error of
the mean.
Genotype at
wasted locus Transgene +/ Weight (g)  SEM
No. of
mice
+/+  12.7  0.3 13
+/+ + 12.1  0.5 13
+/wst  11.5  0.3 15
+/wst + 11.6  0.4 9
wst/wst  7.3  0.6* 8
wst/wst + 11.7  0.4 6
Table 2. Mean grip strength analysis of 25-day-old mice from NSE
–eEF1A2 line B. Grip strength readings for forelimbs and all four
limbs from three tests (measured in newtons) were normalized to
body weight (measured in grams) and expressed 9 100. *P < 0.01
for comparison of wasted mice without the transgene with wild-
type mice; those with the transgene are not significantly different
from wild-type mice. SEM, standard error of the mean.
Genotype at
wasted locus Transgene +/ Grip strength  SEM
No. of
mice
Forelimbs only
+/+  4.9  0.2 13
+/+ + 4.4  0.2 13
+/wst  4.5  0.3 15
+/wst + 4.9  0.3 9
wst/wst  2.8  0.3* 8
wst/wst + 4.4  0.4 6
All four limbs
+/+  8.3  0.4 13
+/+ + 8.3  0.4 13
+/wst  7.5  0.3 15
+/wst + 8.4  0.3 9
wst/wst  6.1  0.4* 8
st/wst + 8.6  0.3* 6
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analysis of all four groups of mice, wild-type mice with
and without the transgene, and wst/wst mice with and
without the transgene, showed that wild-type mice
continued to put on weight until ~ 29 days (the end of
the period studied), regardless of the presence or
absence of the transgene. Wasted mice, in contrast,
failed to gain weight after 22 days, and again, there
was no effect of the transgene (Table 3), suggesting
that there was no difference between the groups in
terms of nutritional status. No wasted mice, transgenic
or nontransgenic, survived beyond 29 days.
Measurements of grip strength in these mice showed
that the presence of physiological levels of eEF1A2 in
muscle only had no measurable effect on muscle func-
tion. Wasted mice with or without the transgene per-
formed significantly less well than wild-type controls
by ~ 27 days, with the rate of decline in forelimb
strength in wasted transgenic mice exactly tracking
that in nontransgenic wasted mice (Table 4; Fig. S2).
We then carried out an analysis of tissues and tissue
sections from limb muscle of the same groups of mice
at different ages. Wasted mice have previously been
found to have reduced hind leg muscle mass relative to
wild-type mice from 23 days [7]. Histologically, this
correlated with a diffuse, nonregional reduction in
myofibre cross-sectional area (atrophy; Fig. 4). Expres-
sion of the transgene in wst/wst mice had no obvious
effect on hind leg muscle mass at 25–26 days or at
26–28 days. The changes seen were consistent with
neurogenic and disuse atrophy, but were too rapid and
acute to impart specificity to the atrophy, given the
shortness of the interval between onset of abnormality
and death in wasted mice. No differences were
observed between wild-type mice with and without the
transgene.
Muscle atrophy and atrogene induction
Although there was no overt difference between
wasted mice without the transgene and those in which
eEF1A2 expression had been restored in muscle with
the HSA promoter, we wanted to determine whether
Fig. 3. Western blots showing expression of eEF1A2 and GAPDH
(as a loading control) in muscle and brain tissue extracts from
transgenic HSA–EEF1A2 mice and nontransgenic mice. The first
lane shows liver, as a negative control for eEF1A2 expression, and
the third lane shows muscle or brain from a wasted nontransgenic
mouse. The second lane shows the relevant tissue from a
nontransgenic wild-type mouse, followed by four wasted
homozygotes carrying the transgene. The transgene is expressed
at levels comparable to those seen in wild-type mice in muscle,
but no expression is seen in brain.
Table 3. Body weights of mice of different genotypes from an
HSA–eEF1A2 line at 25 and 28 days. SEM, standard error of the
mean.
Genotype at
wasted locus Days Transgene +/
Weight (g) 
SEM
No. of
mice
+/+ 25  11.7  0.2 3
+/+ 25 + 11.2  0.9 5
wst/wst 25  6.8  0.4 3
wst/wst 25 + 7.2  0.5 3
+/+ 28  12.7  0.8 6
+/+ 28 + 13.7  0.4 5
wst/wst 28  7.7  0.6 5
wst/wst 28 + 6.6  0.8 3
Table 4. Mean grip strength analysis of 25- and 28-day-old mice
from an HSA–EEF1A2 line. Grip strength readings for forelimbs
and all four limbs from three tests (measured in newtons) were
normalized to body weight (measured in grams) and expressed
9 100. *P < 0.01 for comparison with wild-type nontransgenic
mice. **P < 0.001 for comparison with wild-type nontransgenic
mice. SEM, standard error of the mean.
Genotype at
wasted locus Days Transgene +/
Grip strength 
SEM
No. of
mice
Forelimbs only
+/+ 25 – 4.4  0.8 4
+/+ 25 + 4.6  0.4 3
wst/wst 25  4.4  0.4 3
wst/wst 25 + 3.3  0.6 5
+/+ 28  5.0  0.3 5
+/+ 28 + 4.4  0.1 5
wst/wst 28  2.6  0.5* 5
wst/wst 28 + 2.3  0.5* 3
All four limbs
+/+ 25  8.0  1.0 4
+/+ 25 + 10.5  0.7 3
wst/wst 25  6.1  0.3 5
wst/wst 25 + 5.6  0.5 10
+/+ 28  9.4  0.4 5
+/+ 28 + 9.0  0.2 5
wst/wst 28  5.0  0.5** 5
wst/wst 28 + 4.8  0.2** 3
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known biomarkers of muscle atrophy, such as those
that have been shown to be associated with denerva-
tion atrophy in other mouse models of MND, showed
any changes. We assayed these both in wasted mice as
compared with their wild-type littermates, and also in
wasted mice with and without the transgene. A selec-
tion of markers was chosen, based on the literature.
Atrogin 1 (Fbxo32) [16], muscle RING finger-1
(MuRF1) [16], metallothionein 1 (Mt1) [24], metallo-
thionein 2 (Mt2) [24] and glutathione reductase (Gsr)
[25] have all been shown to be upregulated in condi-
tions of muscle atrophy, whereas muscular chloride
channel 1 (Clc1) has been shown to be downregulated
in muscle disorders, including SMA [26].
The results obtained are shown in Fig. 5A. No mar-
ker showed any significant difference when wild-type
mice with and without the transgene were compared, as
expected. There was high variability within each of the
wasted mouse groups, and although there appeared to
be a trend for markers to be more highly expressed in
wasted mice without the transgene, there were no statis-
tically significant differences between these groups. Clc1
expression, however, which is downregulated in
response to muscle atrophy, was significantly lower in
wasted mice with the transgene than in those without
(P = 0.03). This is counterintuitive, and suggests that
the presence of the transgene is in some way deleterious.
In contrast, it can be seen that, for each of the
markers shown, there was a highly significant change
in expression in wasted mice as compared with their
normal littermate controls. In the most extreme case,
Fbxo32, there was 45- and 76-fold upregulation of the
gene, respectively, in wasted mice with the transgene
(P = 0.009) and without the transgene (P = 0.005) as
compared with wild-type controls, which is consistent
with a substantial degree of denervation-induced atro-
phy in each group.
As eEF1A2, the factor deficient in wasted mice, has
been shown in vitro to be a translation elongation fac-
tor [27], we next investigated whether these highly sig-
nificant changes in gene expression seen at the RNA
level would be reflected at the protein level. As muscle
ceases to express eEF1A1 by approximately 3–4 weeks
of age in mice, the prediction would be that wasted
mouse muscle would cease to be capable of de novo pro-
tein synthesis at about this time, but this has never been
directly tested. We chose Fbxo32 to study, as the dra-
matic upregulation seen by qRT-PCR made this a good
candidate for detecting any differences between wasted
mice without the transgene (and thus with a potentially
diminished capacity for translation in muscle) and those
with the transgene, which should have a normal capac-
ity for protein synthesis. We also examined MuRF1
expression. Both groups of mice were, of course, under-
going muscle atrophy to the same extent, as measured
in the assays described above, and thus represent paral-
lel systems showing muscle response to neuronal dam-
age, but in the presence and absence of muscle eEF1A2.
Figure 5(B) shows the results obtained for Fbxo32
and MuRF1 at both the RNA level and the protein
level. The western blot showed barely detectable pro-
tein levels in wild-type mice, and substantially more
Fbxo32 in wasted mice. However, the increase was less
than sixfold (P = 0.0009), in contrast to the 76-fold
Fig. 4. Periodic acid–Schiff-stained muscle
sections showing reduced fibre size in
wasted mice (right), both with (bottom)
and without (top) the muscle-specific
eEF1A2 transgene.
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upregulation seen at the RNA level. This was shown
more dramatically in the comparison with wasted mice
with eEF1A2 expression in muscle; here, Fbxo32 pro-
tein levels were, in fact, upregulated 20-fold as com-
pared with wild-type controls (P = 0.0006), a value
comparable to the 45-fold upregulation seen at the
RNA level. There was a highly significant difference in
the Fbxo32 protein levels seen in wasted mice with
and without the transgene (P = 0.0001). Similar results
were observed with MuRF1. Here, there was 40-fold
upregulation in nontransgenic wasted mice at the
RNA level (P = 0.009) but nonsignificant upregulation
at the protein level (P = 0.13); transgenic wasted mice,
on the other hand, showed 24-fold upregulation at the
RNA level but nearly fivefold upregulation at the pro-
tein level (P = 0.016; Fig. 5B).
Thus, although there is certainly some conversion of
the RNA-level upregulation seen in wasted mice into
protein, this occurs to a much lesser extent in muscles
that have no eEF1A2, and this represents the first
in vivo evidence of the physiological role of eEF1A2 in
translation. Furthermore, the relatively low levels of
Fbxo32 and MuRF1 proteins, as opposed to their
mRNAs, in wasted muscle suggest that the process of
muscle atrophy can occur without significant upregula-
tion of at least this key atrogene at the protein level.
Discussion
Our study shows that loss of eEF1A2 leads to muscle
atrophy resulting from loss of eEF1A2 in neurons. We
have demonstrated that, whereas expression of an
A B
Fig. 5. (A) qRT-PCR data for markers of muscle atrophy in groups of mice of each genotype plus and minus the muscle-specific eEF1A2
transgene. The y-axis shows the expression level of the gene relative to the reference genes (arbitrary units). Six mice were analysed for
both groups of wasted animals, and four or five for each wild-type group. (B) Quantification of Fbxo32 (upper panel) and MuRF1 (lower
panel) mRNA and protein levels in wasted mice with and without muscle-specific expression of eEF1A2; western blot showing Fbxo32 as
compared with Sypro Ruby loading control (arbitrary units).
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eEF1A2 transgene in neuronal and muscle tissue com-
pletely corrects the wasted phenotype in terms of mus-
cle function and survival, physiological levels of
expression of eEF1A2 in skeletal muscle have no effect
on the course of disease progression or time of death.
Whereas mice with muscle-only expression of eEF1A2
die by 4 weeks, those with both neuronal and muscle
expression are able to survive with no apparent pheno-
typic abnormalities for 12 months. As the same results
were obtained in lines generated from three indepen-
dent founders, we can have some confidence in these
conclusions, even in the absence of a neuron-specific
correction.
Grip strength measurement was a useful and sensitive
assay for muscle function in this study. Wasted mice
showed a clear and consistent loss of grip strength in
comparison with their wild-type littermates. In the NSE
line experiments, which were conducted a year before
the HSA experiments, the difference was clear by
25 days, with no overlap between the groups. In the
HSA experiments, the wasted mice generally survived
for a day or two longer, so the difference between geno-
types was less clear at 25 days, but very marked by
27 days. This fitted well with the pathological observa-
tions of widespread atrophy in the muscles of wasted
mice, which remained unaffected by the presence of
high levels of eEF1A2 transgene expression in muscle.
Our results are similar to a previous study of SMN,
although here the HSA promoter construct gave rise
to high levels of expression in muscle but leaky expres-
sion in brain and spinal cord in certain lines, and the
neuronal promoter used, PrP, also gave leaky expres-
sion in muscle. This study also concluded that expres-
sion of high levels of SMN in muscle fibres alone had
no effect on the SMA phenotype or survival of the
mice in which the correction experiments were per-
formed [8].
In contrast, studies of a spontaneously arising model
of SMA with respiratory distress, the neuromuscular
degeneration (nmd) mutant mouse, showed that,
whereas transgenic expression of Ighmbp2 in neurons
was sufficient to correct the motor neuron degenera-
tion in the mice, they subsequently developed skeletal
myopathy and dilated cardiomyopathy. When a mus-
cle-specific transgene was introduced, this extended the
lifespan of the mice eightfold. However, correction of
the full phenotype, including motor neuron degenera-
tion, required the expression of Ighmbp2 transgenes in
both neuronal and muscle tissue [9,10]. These experi-
ments suggest that the early lethality of nmd/nmd mice
is primarily attributable to the development of dilated
cardiomyopathy rather than the progressive MND
that is also seen.
Our studies of wasted mice, on the other hand, sug-
gest that the phenotypic abnormalities, including the
muscle pathology and muscle function, result from the
loss of eEF1A2 expression in neurons. This makes
wasted mice a useful addition to the spectrum of ani-
mal models of motor neuron degeneration, particularly
in view of the early onset and aggressive nature of the
phenotype. It should also be borne in mind, however,
that the presence of eEF1A2 in muscle could make
some contribution to the phenotype, and that correc-
tion of expression in neurons would not fully amelio-
rate the phenotypic abnormalities.
Analysis of expression levels of genes involved in
muscle atrophy induced by motor neuron degenera-
tion, surgical denervation and other triggers provides
further insights into the function of eEF1A2, and into
the mechanisms of muscle atrophy. First, the 76-fold
upregulation of Fbxo32 seen in muscle of wasted mice
as compared with wild-type littermates results in a less
than sixfold upregulation at the protein level. This
contrasts with the situation seen in wasted mice with
restored expression of eEF1A2 in muscle, which show
a smaller, 45-fold change in Fbxo32 mRNA, and yet a
20-fold change in the level of Fbxo32 protein. Thus,
whereas Fbxo32 mRNA levels are almost twice as high
in wasted mice without the transgene, Fbxo32 protein
levels are over threefold lower in these mice than in
those expressing eEF1A2 in muscle. This strongly sug-
gests that the absence of eEF1A2 in muscle severely
compromises the ability of this tissue to carry out
de novo protein synthesis, confirming, for the first time
in vivo, the biochemical characterization of eEF1A2 as
a translation elongation factor. The modest induction
that is seen in wasted muscle is presumably attribut-
able to residual amounts of eEF1A1; although this has
largely gone by 21 days, retraction of nerves from
motor nerve endplates is seen from at least 17 days, so
the trigger for upregulation of Fbxo32 would precede
the complete downregulation of eEF1A1.
Importantly, we can use this system of wasted mice
with (HSA–eEF1A2 transgene) and without (nontrans-
genic) eEF1A2 in muscle as a system for studying the
molecular basis of the programme of events underly-
ing muscle atrophy. Deletion of either Fbxo32 or
MuRF1 in mice ameliorates the muscle damage result-
ing from denervation over a period of 7–14 days, sug-
gesting that the products of these genes are necessary
for the execution of the full programme of muscle
atrophy [18]. The genes encode ubiquitin ligases,
whose role is to target contractile proteins for degra-
dation by the proteasome. Whereas approximately
similar, extremely high, levels of induction are seen at
the mRNA level in wasted mice with and without an
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eEF1A2 transgene in muscle, there is a 3.4-fold differ-
ence in the level of Fbxo32 protein seen in these two
groups of mice. The degree of upregulation in the
nontransgenic mice is very modest, especially when
compared with the qRT-PCR results, and yet atrophy
as determined by pathology and grip strength is indis-
tinguishable between the transgenic and nontransgenic
wasted mice. As there is no reason to think that the
mRNAs for these genes are functional, these data sug-
gest that, although these atrogenes may be essential
for many forms of muscle atrophy, this is not inevita-
bly the case. We suggest that, perhaps, loss of protein
synthetic capacity in muscle should be considered as
passive muscle atrophy, whereas mechanisms involving
atrogene induction and proteolysis should be consid-
ered to be active muscle atrophy. Further studies using
this system are likely to be very useful for understand-
ing atrogene function.
The question of whether wasted mice constitute a
useful model for motor neuron degeneration remains
an open one, although our results certainly point more
to a neurodegenerative phenotype than to one of pri-
mary muscle atrophy. A common (and valid) criticism
of the model is that no mutations have been found in
the gene encoding eEF1A2 in human ALS patients.
However, the recent discoveries [11] of a heterozygous
missense mutation in eEF1A2 in two separate individ-
uals with intractable early-onset epilepsy and severe
intellectual disabilities may shed some light on this.
The mutation is predicted to give rise to loss of func-
tion; if this is the case, then homozygous loss of func-
tion mutations (equivalent to wasted mice) would be
unlikely to be seen in human populations.
Experimental procedures
Constructs
A pUC19–EEF1A2 plasmid was created by subcloning the
18 891-bp eEF1A2 gene from a human PAC. This backbone
was used for generation of the transgenic construct. An AgeI
site located 102 bp upstream of the second exon (the first
coding exon) of eEF1A2 was identified as a suitable unique
site for insertion of the new promoter. The promoter region
of eEF1A2 was removed by digestion with HindIII and AgeI.
The NSE promoter (a 1946-bp fragment of the rat NSE pro-
moter generated by PCR and flanked with HindIII and AgeI
sites) was then inserted into this site. The HSA promoter was
a kind gift from J. Tinsley (MRC Harwell, Oxfordshire, UK)
[28], and covered the region 2000 to +239. The transgene
constructs were excised from the vector and gel purified,
diluted to 2 nglL1 with microinjection buffer, and purified
in a Spinex column in preparation for microinjection.
Mice
Mice were housed in the Biomedical Research Facility at
the University of Edinburgh. All mice were maintained in
accordance with Home Office regulations, and all protocols
were approved by the local ethics committee of the Univer-
sity of Edinburgh. Embryo transfer was carried out with
short-term recovery anaesthesia, and analgesia when needed
postoperatively. Transgenic and mutant mice were closely
observed for overall clinical condition, and were killed
when necessary to avoid suffering.
Transgenic mouse generation
Transgenic mice were made by standard pronuclear injec-
tion into oocytes derived from (C57BL/6 9 CBA)F1 mice.
Founder mice that carried an intact transgene as estab-
lished by PCR genotyping and expression analysis were
then crossed to +/wst mice, and then intercrossed to derive
transgene-positive wst/wst mice.
Grip strength
A grip strength meter (Bioseb, http://www.bioseb.com) was
used to measure limb muscle strength. Forelimbs and all
four limbs were measured separately by lowering the mouse
onto the grid until it grasped it with either front limbs or
all limbs. The tail was then pulled steadily from the grid in
one fluid movement until the mouse released its grip. The
maximum force in newtons required for the mouse to relin-
quish its grip was recorded, and the readings were normal-
ized to body weight. Measurements were made three times
per mouse, with a 1-min break between trials, and the
results were averaged. Significance was estimated by t-tests
with PRISM GRAPHPAD (San Diego, CA, USA).
Western blots
Western blotting was carried out with antibodies and tech-
niques as previously described [6], with the addition of
anti-eEF1A2 Ig from Genetex (Irvine, CA, USA) (1 : 2000)
and anti-Fbxo32 Ig from Abcam (Cambridge, UK)
(1 : 2000). Calbiochem (Darmstadt, Germany) Rapid Step
ECL was used for detection, and either GAPDH (Chem-
icon, Watford, UK; 1 : 30000) or Sypro Ruby (later blots)
were used as loading controls. Quantification of band
intensity was carried out with GENESNAP (Cambridge, UK)
and GENETOOL (Cambridge, UK), or IMAGE J (http://
rsbweb.nih.gov/ij/), and significance assessed with two-
tailed t-tests for samples of equal variance.
Pathology
Sections of deep digital flexor forelimb muscle were pre-
pared from wasted, transgenic and control mice, and
stained with Periodic acid–Schiff.
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qRT-PCR
RNA was extracted from mouse quadriceps muscle with
the RNeasy Mini Kit (Qiagen, Manchester, UK). During
extraction, RNA was treated for 15 min with DNase I
(Qiagen) to minimize any DNA contamination. The RNA
concentration in samples was assessed with a Nano-
Drop 1000 device (Thermo Scientific, Loughborough, UK).
In order to synthesize cDNA from mRNA, the High-
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Paisley, UK) was used, according to the manu-
facturer’s instructions. qRT-PCR was performed with a
standard curve method for the quantification of gene
expression. Primer sequences were taken from the literature
or commercial sources as follows: Fbxo32 [29], Ankrd1 [30],
Gsr [31], Mt1 [32], Cic1 [33], Tubb [34], and MuRF1 (Qia-
gen assay QT00291991) All qRT-PCR assays complied with
the Minimum Information for Publication of Quantitative
Real-Time PCR experiments guidelines [35]. For gene
expression normalization, we used the geometric average of
the combination of the two most stable reference genes,
b2-microglobulin (B2 m), and b-tubulin (Tubb2). These
genes were identified with the GENORM program [36]. PCR
product accumulation was detected with fluorescent SYBR
Green dye (Finnzymes, Loughborough, UK). A series of
diluted cDNAs was used to construct a standard curve for
each pair of primers, and only those with efficiencies from
90% to 105% were used for further analysis. The result for
each target gene was normalized against the reference
genes, and the DDCT method was used to determine rela-
tive changes in transcriptional expression. Significance test-
ing was carried out with the Mann–Whitney/Wilcoxon
rank sum test for populations that are not normally distrib-
uted.
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